DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

RHHBY·Roche Holding AG

$.
-. (-.%)
High
$53.13
Open
$53.10
Market Cap
266.66B
52W High
$334.80
Low
$52.89
P. Close
$53.34
P/E
20.70
52W Low
$291.00
Fwd P/E
-
Mean Target
-
Technical Score (1D)
23
SELL
News Sentiment
55
BULLISH
No summary available yet.
Earnings Summary
Roche Holding AG, a global healthcare leader established in 1896 and headquartered in Basel, Switzerland, operates significantly within the pharmaceuticals and diagnostics sectors. The company focuses on developing innovative treatments for oncology, immunology, and neurological disorders, complemented by a robust diagnostics division that aids in disease detection and management. This integrated approach positions Roche strongly within the competitive healthcare industry. Roche's recent financial performance shows a mixed trend. In Q1 2026, the company reported revenue estimates of $15.735 billion, though actual results were not provided. Looking back, the most recent reported quarters indicate a deceleration in revenue growth compared to the prior two periods, though specific figures for EPS and revenue actuals are not available for direct comparison. Historically, Roche has demonstrated a strong revenue growth trajectory year-over-year, driven by its pharmaceutical segment, particularly oncology therapies from Genentech. While specific beat/miss patterns against analyst estimates for EPS and revenue are not detailed in the provided data, the company's pipeline advancements suggest continued potential. Recent news highlights significant developments, including the "All Eyes on DME" campaign by Genentech to raise awareness for diabetic macular edema, potentially boosting demand for related treatments. Furthermore, Roche's experimental multiple sclerosis drug, fenebrutinib, has shown promising relapse reduction in Phase III trials, though safety concerns related to reported deaths warrant close monitoring. Advancements in Gazyva's application for lupus erythematosus and Enspryng's efficacy in MOGAD trials also point to future growth drivers. Investors will be watching for the impact of the DME awareness campaign on sales and any further regulatory developments or clarifications regarding the safety profile of fenebrutinib. Key will be the company's ability to translate pipeline successes into market share and sustained revenue growth, particularly in its core therapeutic areas.

EPS

EstBeatMiss
No data available
QtrEstActual+/−
Q1'26 - - -

Revenue

EstBeatMiss
$15.7B$15.7B$15.7B$15.7B$15.7BQ1'26
QtrEstActual+/−
Q1'26$15.7B - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RHHBY Stock Snapshot

RHHBY is currently trading at $52.92, giving Roche Holding AG a market cap of 266.66B and a P/E ratio of 20.7. Today's range spans $52.89–$53.13, with shares opening at $53.10 and moving down $0.42 (0.8%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 55/100.

Over the past year RHHBY has traded between $291.00 and $334.80 - the current price is -81.8% off the 52-week low and -84.2% from the high.

The path of least resistance for Roche Holding AG (RHHBY) is currently lower - 23/100 (SELL), neutral sentiment (55/100), price $52.92 (near 52-week lows within $291.00–$334.80). The current P/E ratio stands at 20.7. At 266.66B in Healthcare market cap, this large-cap name is in the zone where portfolio risk managers - not just traders - are making decisions. Trimming positions on technical deterioration is standard practice at this size, and the current setup gives them a clear rationale to act.

Analyst coverage for RHHBY becomes a double-edged factor in a SELL phase: at 266.66B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 23/100 technical reading and neutral sentiment (55/100) at $52.92 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $291.00–$334.80 range establishes where that repricing lands.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…